StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UPDATE: Morgan Stanley Upgrades Fulcrum Therapeutics (FULC) to Overweight
August 11, 2021 3:27 AM
(Updated - August 11, 2021 5:49 AM EDT)
Morgan Stanley analyst Matthew Harrison upgraded Fulcrum Therapeutics (NASDAQ: FULC) from ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Hot Comments
Hot Upgrades
Upgrades
Next Articles
Fulcrum Therapeutics Inc. (FULC) Prices 6.6M Share Offering at $19/sh
August 12, 2021 5:46 AM
Form SC 13G Fulcrum Therapeutics, Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
August 10, 2021 5:05 PM
Fulcrum Therapeutics Inc. (FULC) Announces $100M Proposed Public Offering of Common Stock
August 10, 2021 4:24 PM
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
August 10, 2021 4:24 PM
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
August 10, 2021 4:24 PM
Fulcrum Therapeutics (FULC) PT Raised to $30 at Credit Suisse
August 10, 2021 4:17 PM
Fulcrum Therapeutics' (FULC) FTX-6058 Data is Strong Start, Sets Stage for In-Patient Trial in 4Q21 - Analyst
August 10, 2021 1:34 PM
Fulcrum Therapeutics Inc. (FULC) Halted on LUDP, Up 114%
August 10, 2021 11:27 AM
Fulcrum Therapeutics (FULC) PT Raised to $45 at Stifel
August 10, 2021 11:00 AM
Fulcrum Therapeutics Inc. (FULC) Climbs 48%
August 10, 2021 8:29 AM
Form 10-Q Fulcrum Therapeutics, For: Jun 30
August 10, 2021 7:09 AM
Fulcrum Therapeutics Inc. (FULC) Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
August 10, 2021 7:07 AM
Fulcrum Therapeutics Inc. (FULC) Tops Q2 EPS by 2c
August 10, 2021 7:05 AM
Form 8-K Fulcrum Therapeutics, For: Aug 10
August 10, 2021 7:02 AM
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 10, 2021 7:01 AM
Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results
August 10, 2021 7:01 AM
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
August 10, 2021 7:00 AM
Fulcrum Therapeutics Announces Positive Interim Results from Phase 1 Healthy Adult Volunteer Trial of FTX-6058 for Sickle Cell Disease
August 10, 2021 7:00 AM
